Study #2023-0997
Open-label phase 2 study of Avutometinib (RAF/MEK clamp) in combination with Defactinib (FAK inhibitor) and Cetuximab in patients with unresectable, anti-EGFR-refractory advanced colorectal cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Defactinib, Cetuximab, Avutometinib
Description
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Colorectal Cancer
Study phase:
Phase II
Physician name:
Christine Parseghian
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-467-0332
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.